Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Zymergen

Biotech & Life Sciences · Emeryville, United States · Founded 2013 · IPO 2021 Unicorn

Technology company unlocking the power of biology

Valuation
$226M
Market cap · 2026
Revenue
$17M
Latest reported FY

Investors

22 investors on Zymergen's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 5 investors entered at this stage
David Beyer
Genoa Ventures
DCVC
Jesse Robbins
Jenny Rooke
Series B+ 11 investors entered at this stage

Global footprint

Where Zymergen has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States94.8%
🇮🇳 India3.5%
🇳🇱 Netherlands3.4%
3 countries shown

Patent intelligence

$9M patent portfolio · 38 active families

Estimated portfolio value
$9M
4.2% of market cap · 289.3× smaller than top peer Illumina ($2.7B)
38 active patent families
Where Zymergen innovates Biological organismBioinformaticsMolecular biologyMicroorganismMicrobiology

Where Zymergen concentrates vs peers

Each axis is a top-10 topic across Zymergen and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Zymergen

An AI-synthesized read of the highest-engagement posts about Zymergen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zymergen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.